BiotechTube
U-Ploid

U-Ploid

Cambridge, United Kingdom· Est.
u-ploid.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

U-Ploid is a private, pre-clinical stage biotech founded in 2018 in Cambridge, UK, targeting the age-related infertility crisis. The company's lead program is a therapeutic designed to reduce chromosomal errors (meiotic aneuploidy) in eggs, which is the primary cause of IVF failure in women over 33. By improving egg quality, U-Ploid seeks to significantly increase IVF success rates for older women, addressing a major unmet need in reproductive medicine with a scalable treatment compatible with current clinical workflows.

Reproductive HealthFertility

Technology Platform

Platform focused on developing therapeutics to reduce meiotic aneuploidy (chromosomal errors) in human eggs, thereby improving egg quality and IVF outcomes. Designed for seamless integration into existing IVF protocols.

Opportunities

The global trend of later childbearing creates a large, growing market of women over 33 seeking IVF, where current success rates are low.
A successful therapeutic that improves egg quality could become a high-value, standard-of-care add-on in IVF cycles worldwide, addressing a major unmet need and generating significant revenue.

Risk Factors

High scientific risk that the novel therapeutic mechanism fails to demonstrate efficacy or safety in human trials.
Regulatory pathway for a first-in-class reproductive therapeutic is uncertain.
Competition from entrenched diagnostic technologies (like PGT-A) and potential future therapies from other companies.

Competitive Landscape

The direct competitive landscape for therapeutics targeting egg aneuploidy is nascent but emerging. The primary current alternative is Preimplantation Genetic Testing for Aneuploidy (PGT-A), a diagnostic tool that selects viable embryos but does not improve egg quality. U-Ploid's success would create a new therapeutic category, potentially competing with or complementing PGT-A.

More companies in United Kingdom →